www.MetabolicCareToday.com
@metaboliccare.bsky.social
Metabolic Care Today features breaking news, commentary, and updates to inform healthcare professionals on the latest research and best clinical practices in the metabolic disorder space | www.MetabolicCareToday.com
Reposted by www.MetabolicCareToday.com
The combined action of tyrosine kinase inhibitors (#TKIs) on #thyroid gland function & peripheral deiodinases generates a unique phenotype of primary #hypothyroidism characterised by increased TSH concentrations & a reduced T3 to T4 ratio www.thelancet.com/journals/lan...
#MedSky #EndoSky #OncSky
#MedSky #EndoSky #OncSky
The unique signature of tyrosine kinase inhibitor-induced hypothyroidism
Tyrosine kinase inhibitors (TKIs) are anti-cancer agents that inhibit the activity
of oncogenic protein kinases. Thyroid hormone abnormalities are common during treatment
with TKIs, typically manifest...
www.thelancet.com
August 27, 2025 at 2:53 PM
The combined action of tyrosine kinase inhibitors (#TKIs) on #thyroid gland function & peripheral deiodinases generates a unique phenotype of primary #hypothyroidism characterised by increased TSH concentrations & a reduced T3 to T4 ratio www.thelancet.com/journals/lan...
#MedSky #EndoSky #OncSky
#MedSky #EndoSky #OncSky
Canadian Obesity guidelines vs. the Lancet Commission:
Beverly Tchang, MD, unpacks differences in defining and treating obesity.
🎥 Watch here: www.docwirenews.com/post/obesity...
Beverly Tchang, MD, unpacks differences in defining and treating obesity.
🎥 Watch here: www.docwirenews.com/post/obesity...
Obesity Guidelines in Focus: Defining Disease and Clinical Boundaries | Docwire News
Beverly Tchang, MD, compares Canadian Obesity guidelines with the Lancet Commission on defining and treating obesity.
www.docwirenews.com
August 27, 2025 at 6:19 PM
Canadian Obesity guidelines vs. the Lancet Commission:
Beverly Tchang, MD, unpacks differences in defining and treating obesity.
🎥 Watch here: www.docwirenews.com/post/obesity...
Beverly Tchang, MD, unpacks differences in defining and treating obesity.
🎥 Watch here: www.docwirenews.com/post/obesity...
📊 mweintraubmd.bsky.social reviews ATTAIN-1 & ACHIEVE-1: oral GLP-1 #orforglipron shows weight loss & CV benefit but falls short of injectables. Caution urged on efficacy. @nyulangone.bsky.social
🔗 www.docwirenews.com/post/orforgl...
🔗 www.docwirenews.com/post/orforgl...
Orforglipron Phase 3 Data: Dr. Michael Weintraub Reviews ATTAIN-1 and ACHIEVE-1 Findings | Docwire News
Dr. Michael Weintraub reviews phase 3 ATTAIN-1 and ACHIEVE-1 data on orforglipron in obesity and type 2 diabetes.
www.docwirenews.com
August 21, 2025 at 3:09 PM
📊 mweintraubmd.bsky.social reviews ATTAIN-1 & ACHIEVE-1: oral GLP-1 #orforglipron shows weight loss & CV benefit but falls short of injectables. Caution urged on efficacy. @nyulangone.bsky.social
🔗 www.docwirenews.com/post/orforgl...
🔗 www.docwirenews.com/post/orforgl...
GLP-1 RAs: Big benefits, small GI risks.
📊 +2 cholelithiasis & +4 GERD cases per 1,000 patients.
No rise in pancreatitis or bowel obstruction.
Dr. Cho Han Chiang explains how to weigh the trade-offs.
🎥 Watch here: www.docwirenews.com/post/balanci...
📊 +2 cholelithiasis & +4 GERD cases per 1,000 patients.
No rise in pancreatitis or bowel obstruction.
Dr. Cho Han Chiang explains how to weigh the trade-offs.
🎥 Watch here: www.docwirenews.com/post/balanci...
Balancing Benefits and GI Risks: What Clinicians Should Know About GLP-1 RAs | Docwire News
Dr. Cho Han Chiang reviews GI risks of GLP-1 RAs, balancing safety with their metabolic and cardiovascular benefits.
www.docwirenews.com
August 13, 2025 at 2:28 PM
GLP-1 RAs: Big benefits, small GI risks.
📊 +2 cholelithiasis & +4 GERD cases per 1,000 patients.
No rise in pancreatitis or bowel obstruction.
Dr. Cho Han Chiang explains how to weigh the trade-offs.
🎥 Watch here: www.docwirenews.com/post/balanci...
📊 +2 cholelithiasis & +4 GERD cases per 1,000 patients.
No rise in pancreatitis or bowel obstruction.
Dr. Cho Han Chiang explains how to weigh the trade-offs.
🎥 Watch here: www.docwirenews.com/post/balanci...
New research out of @soleimanpourlab.bsky.social links beta cell failure in T2D to mitochondrial—not ER—protein misfolding. Boosting LONP1 protected cells & restored insulin function, pointing to a novel therapeutic path.
🎥 Watch: www.docwirenews.com/post/targeti...
🎥 Watch: www.docwirenews.com/post/targeti...
Targeting LONP1 to Protect Beta Cells: A New Therapeutic Avenue in Type 2 Diabetes | Docwire News
Study finds mitochondrial protein misfolding drives beta cell failure in T2D, making LONP1 a potential therapy target.
www.docwirenews.com
August 12, 2025 at 2:46 PM
New research out of @soleimanpourlab.bsky.social links beta cell failure in T2D to mitochondrial—not ER—protein misfolding. Boosting LONP1 protected cells & restored insulin function, pointing to a novel therapeutic path.
🎥 Watch: www.docwirenews.com/post/targeti...
🎥 Watch: www.docwirenews.com/post/targeti...
🚨 New GLP-1 pill shows big results:
@elilillyandcompany.bsky.social's once-daily oral #orforglipron led to up to 27.3 lbs weight loss in 72 weeks in phase 3 #ATTAIN1, with improvements in heart risk markers. A potential game-changer for obesity care.
docwirenews.com/post/lillys-...
#Obesity #GLP1
@elilillyandcompany.bsky.social's once-daily oral #orforglipron led to up to 27.3 lbs weight loss in 72 weeks in phase 3 #ATTAIN1, with improvements in heart risk markers. A potential game-changer for obesity care.
docwirenews.com/post/lillys-...
#Obesity #GLP1
docwirenews.com
August 7, 2025 at 10:38 PM
🚨 New GLP-1 pill shows big results:
@elilillyandcompany.bsky.social's once-daily oral #orforglipron led to up to 27.3 lbs weight loss in 72 weeks in phase 3 #ATTAIN1, with improvements in heart risk markers. A potential game-changer for obesity care.
docwirenews.com/post/lillys-...
#Obesity #GLP1
@elilillyandcompany.bsky.social's once-daily oral #orforglipron led to up to 27.3 lbs weight loss in 72 weeks in phase 3 #ATTAIN1, with improvements in heart risk markers. A potential game-changer for obesity care.
docwirenews.com/post/lillys-...
#Obesity #GLP1
🚨 Once-weekly semaglutide led to major weight loss & improved glucose control in adults with #T1D + obesity—without added risk.
✅ -8.8 kg weight
✅ ↑ time-in-range
✅ No ↑ in severe hypo or DKA
Big step forward in #T1D care.
🔗 www.docwirenews.com/post/once-we...
#diabetes #GLP1 #semaglutide @nejm.org
✅ -8.8 kg weight
✅ ↑ time-in-range
✅ No ↑ in severe hypo or DKA
Big step forward in #T1D care.
🔗 www.docwirenews.com/post/once-we...
#diabetes #GLP1 #semaglutide @nejm.org
Once Weekly Semaglutide Injection Trial Shows Favorable Results in Management of Type I Diabetes and | Docwire News
Once-weekly semaglutide improved weight, insulin needs, and glycemic control in adults with T1D and obesity.
www.docwirenews.com
July 24, 2025 at 4:20 PM
🚨 Once-weekly semaglutide led to major weight loss & improved glucose control in adults with #T1D + obesity—without added risk.
✅ -8.8 kg weight
✅ ↑ time-in-range
✅ No ↑ in severe hypo or DKA
Big step forward in #T1D care.
🔗 www.docwirenews.com/post/once-we...
#diabetes #GLP1 #semaglutide @nejm.org
✅ -8.8 kg weight
✅ ↑ time-in-range
✅ No ↑ in severe hypo or DKA
Big step forward in #T1D care.
🔗 www.docwirenews.com/post/once-we...
#diabetes #GLP1 #semaglutide @nejm.org